Click me
Transcribed

Neostem (NBS) Stock Investment Infographic

Neostem Neestem Invest VALUE PAST HEALTH No noteworthy features. COMPANY Neostem, Inc. NeoStem, Inc., a biotechnology company, develops cell based therapeutics. TIOKER NasdaqCM:NBS COMPETITORS Celgene Mesoblast VALUE VALUE VALUE Neostem's calculated fair value and its price relative to the stock market. CALCULATED FAIR VALUE The fair value of Neostem shares based on actual and anticipated performance. O O It is not possible to calculate the intrinsic value for Neostem. This could be due to the earnings or growth being negative. The share price is $3.75. PRICE RELATIVE TO MARKET The relative price of Neostem shares compared to stock market averages. PRICE BASED ON PAST EARNINGS PRICE BASED ON EXPECTED GROWTH No data or negative Growth Earnings Neostem O No oarnings or negative earnings. O Good value based on expected growth. O No earnings or negative earnings. PRICE BASED ON VALUE OF ASSETS Assets O Pharmaceuticals industry average Neostem Good value based on assets compared to the Pharmaceuticals industry average. FUTURE PERFORMANCE Neostem's expected performance in the next 1 to 3 years, based on estimates from 4 analyst(s). -5% Estimated 1 year earnings growth is above the low risk savings rate, plus a premium to keep pace with inflation. Expected earnings growth over 3 years. O 3 year earnings growth is expected to be negative. 1&3 YEAR ESTIMATED GROWTH IN EARNINGS Neostem I Low risk savings rate + inflation (4.6% pa) 14.4% 7.4% 4.6% -4.7% +1 year +3 years YEAR ON YEAR ESTIMATED GROWTH IN EARNINGS O 75% 2012 2013 2014 2015 2016 -50% FUTURE PROFIT ESTIMATE $100M Estimated Estimated Revenue Estimated Profit $-100M 211 2012 2013 2014 2015 2016 2017 O Profit is not expected to increase more than 50% in 1 year's time. O Profit is not expected to increase more than 100% in 3 years time. FUTURE PERFORMANCE +3 years +1 year Return on Equity Return an Equity Pharmaceuticals industry averag Neostem O Information is not available. O Information is not available. O No 3 year Return on Equity data available. PAST PERFORMANCE Neostem's performance over the past 5 years. O PAST 1 YEAR GROWTH GROWTH ANALYSIS O Neostem's profit growth has not matched the industry average in the past year. 26% 21% Neostem's 1 year profit growth is less than its 5 year average (16% vs 26%). 16% O Neostem has improved profit in the past 5 years. INeostem 5 year average Neostem 1 year I Pharmaceuticals industry 1 year average PROFIT HISTORY $75M Revenue Profil $-75M 2008 2009 2010 211 2012 2013 2014 PERFORMANCE LAST YEAR sturn rurn rurn Assets Equity Capital Pharmaceuticals industry averag Neostem O Negative return on shareholders funds (ROE) last year. O Neostem had negative or no return on assets (ROA) last year. O Return based on revenue producing assets (ROCE) is negative or zero. HEALTH Neostem's financial health and their level of debt, O NET WORTH Short term Long term INet worth $150M Net worth $0 2008 2009 211 2014 Liabilities Assets 2010 2012 2013 O Neostem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets. O Neostem's long term commitments exceed its cash and other short term assets. BALANCE SHEET O ASSETS LIABILITIES AND SHARES Cash + Investments Debt Other Assets Shares Other unpaid ners u Physical Assets vento opliers unpa O Low level of unsold assets O Total debt is covered by short term assets. HISTORICAL DEBT $150M Net worth (Equity) Debt $0 2008 2009 2010 2012 2014 211 2013 O The level of debt (27%) compared to net worth is satisfactory (less than 40%). O The level of debt compared to net worth has increased over the past 5 years. O Total debt is not well covered by annual operating cash flow (less than 20% of total debt). O Company earns more interest than it pays. INCOME Neostem's current dividend yield, its volatility and sustainability. O ANNUAL DIVIDEND INCOME DIVIDEND AMOUNT O Paying below low risk savings rate. (2.59%) 0% Your expected annual O Paying below the markets top dividend payers. (4.6%) income from Neostem dividends. HISTORICAL DIVIDEND YIELD 0.4% 0% -5 yrs -4 yrs -3 yrs -2 yrs yr Now + Neostem + Pharmaceuticals industry average O Not paying a notable dividend. O Not paying a notable dividend. CURRENT PAYOUT TO SHAREHOLDERS FUTURE PAYOUT TO SHAREHOLDERS -0% 0% Now +3 years O Not paying a notable dividend. O Not paying a notable dividend. MANAGEMENT Neostem's CEO's compensation, management and board of directors. CEO Robin Smith COMPENSATION $1,235,500 49 AGE CEO BIO O Dr. Robin L. Smith, M.D., MBA, Ro, has been Executive Chairman and Chief Executive Officer of Neostem, Inc. at Amorcyte, LLC and Progenitor Cell Therapy, LLC since June 2, 2006. Dr. Smith served as Chief Operating Officer - Ip2m Division and Senior Vice President - Ip2m Division at Dialog Group, Inc. Dr. Smith serves as Member of Advisory Board at Wellfleet Partners Investment Arm. They serves as Member of Medical Advisory Board at House of Brussels Chocolates Inc. They serves as Member of Advisory Board at Wellfleet Partners, Inc. They serves as Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating & Governance Committee at Signal Genetics, Inc. They previously served at Fogdog, Inc. They previously served as Former Chief Medical Officer and Executive Vice President at HealthHelp Inc. They previously served as Chief Executive Officer at IP2M Inc. L.] CEO COMPENSATION $1OM SOM 2008 2009 2010 2011 2012 2013 Total Compensation ISalary I Neostem's Performance (Relative) O CEO's compensation has been consistent with company performance over the past year. O CEO's compensation appears reasonable. MANAGEMENT TEAM TENURE BOARD OF DIRECTORS TENURE Average tenure of the Neostem management team: Average tenure of the Neostem board of directors: vears 3.2 vears O The tenure for the Neostem management team is about average. O The tenure for the Neostem board of directors is about average. MANAGEMENT TEAM O BOARD OF DIRECTORS O Robin Smith Rob Dickey Robin Smith Andrew Pecora TITLE TITLE TITLE TITLE Executive Chairman and Chief Chief Financial Officer Executive Chairman and Chief Chief Visionary Officer Executive Officer COMPENSATION Executive Officer COMPENSATION COMPENSATION $435,371 COMPENSATION $873,014 $1,235,500 AGE $1,235,500 AGE AGE 58 AGE 57 49 49 Bob Preti Doug Losordo George Smith Richard Berman TITLE TITLE TITLE TITLE Medical Director of Laboratory Operations and Member of Medical COMPENSATION Advisory Board Chief Scientific Officer Chief Medical Officer Independent Director COMPENSATION COMPENSATION $637,455 $705.416 $142,200 AGE AGE AGE AGE 57 56 78 71 Andrew Pecora Stephen Potter Ric Myers Drew Bernstein TITLE TITLE TITLE TITLE Chief Visionary Officer Executive Vice President Lead Director Independent Director COMPENSATION COMPENSATION COMPENSATION COMPENSATION $873,014 $90,703 $142,200 $139,866 AGE AGE AGE AGE 57 57 68 57 SOCIAL Analyst Highlights - Week 49 - Healthcare (Part I) http://t.co/xWIB4gjphH $NBS ŞAEZS ŞIDRA SDVAX SABBV I love the first paragraph of this piece on NBS by @zzlangerhans: http://t.co/KTDAwftDpM Brad Loncar (oradloncar) - 14 hours ago Smarter Analyst (SmarterAnalyst) - 8 hours ago My latest assessment of SNBS, in two parts no less http://t.co/ieu25Sdoki . tweeps familiar with the story skip to the first comment. Wow http://t.co/PeRPkZkWiw just posted last weeks results. +429%. Crazy. They offer a free trial too. SVIP ŞQTM ŞAUQ ŞNBS ŞREXX SSIMH Tony Friedrman (zzlangerhans) - 23 hours ago Trader News Daily (@TraderNewsDaily) -1 day ago Platinum Memberships Rose, After 528% Gains On Penny Stocks, In One Month! Big Update: http://t.co/2W3yKD2d5Q $MMS ŞMOV SNBS Platinum Memberships Rose, After 528% Gains On Penny Stocks, In One Month! Big Update: http://t.co/2W3yKD2d5Q $MMS $MOV SNBS Stockaholics (OStockaholics)- 1 day ago Stockaholics (OStockaholics) - 1 day ago Wow http://t.co/PeRPkZkWiw just posted last weeks NeoStem Trading Down 4.5% Following Insider Selling SNBS http://t.co/ZZ297576UC results. +429%. Crazy. They offer a free trial too. SVIP ŞQTM ŞAUQ ŞNBS SREXX SSIMH US Banking News (@AmericanBanking)- 2 days ago Trader News Daily (@TraderNewsDaily) - 2 days ago COMPANY INFO DESCRIPTION NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer NeoStem immunotherapy product to enhance the destruction of cancer initiating cells; a Phase Il ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase Il immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York. DETAILS MAP Montréalo MAINE NOVA SCOTIA NISNO MICHIGAN Toronto Neostem, Inc. NBS Name: OChicago Ticker: OHIO"ENNSYLVANIA CTRI Exchange: NasdagCM Founded: 1980 Market Cap: $144 millionm Website: www.neostem.com 420 Lexington Avenue, New York, United WEST VIRGINIA KENTUCKY VIRGINIA States Map data 62014 Google OFFICE STAFF 11 Neostem employees. % 108 Google INDUSTRY Industry: Biotechnology Sector: Pharmaceuticals, Biotechnology and Life Sciences © 2014 SIMPLY WALL STREET PTY LTD, STANDARD & POOR'S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED Simply Wall Street Pty Ltd is a Corporate Authorised Representative (No. 467183) of The Intelligent Investor Publishing Pty Ltd (AFSL No. 282288) The information given by Simply Wall St and provided in this web platform is general information only and it does not take into account your investment objectives, financial situation or needs. You should seek independent financial and legal advice to consider if an investment is appropriate for your personal circumstances. Copyright 2014, Standard & Poor's Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall SaP be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber's or others' use of S&P Capital IQ. (2014) FUTURE INCOME

Neostem (NBS) Stock Investment Infographic

shared by simplywallst on Dec 09
52 views
0 shares
0 comments
An infographic looking at biotech company Neostem (NasdaqCM:NBS) as a potential stock investment.

Category

Education
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size